Growing evidence suggests the importance of microRNAs (miRNAs) in stress signaling pathways. Transforming growth factor-β (TGF-β) is a potent cytokine that promotes the development of skeletal muscle fibrosis after acute contusion. However, how miRNAs are involved in TGF-β signaling and confer the robustness of TGF-β-induced fibrotic response remains to be fully elucidated. Here, we demonstrated that miR-146a-5p (miR-146) levels were reduced in a fibrotic mouse model after acute muscle contusion. It was also found that TGF-β treatment decreased the expression of miR-146 in vitro in a dose-and time-dependent manner. In addition, overexpression of Smad3 and Samd4, two key players in TGF-β signaling, suppressed the expression of miR-146 in muscle cells. Overexpression of miR-146 inhibited the expressions of fibrosis markers both in vitro and in vivo. Moreover, increase in the expression of miR-146 in muscle cells was able to attenuate the effect of TGF-β on the expressions of fibrosis markers. Mechanistic analysis revealed that Smad4 is a direct target of miR-146 in muscle cells. Furthermore, the anti-fibrotic effect of miR-146 could be blocked by overexpression of Smad4 in vivo. These results suggest that Smad4 is down-regulated by miR-146 in skeletal muscle. Taken together, our results indicate that the anti-fibrotic miR-146 is a component of TGF-β signaling. It is down-regulated by Smad protein, and can inhibit the expression of Smad4. Our study suggests that miR-146 might have a therapeutic potential to reduce skeletal muscle fibrosis after injury.
Introduction
As a prevalent sports injury, skeletal muscle injury can be caused by contusion, laceration, or strain. The healing process consists of three consistent stages, i.e. inflammation stage, regeneration stage, and scar formation phase [1] . However, the biomechanical properties of recovered muscle are weakened due to the existence of fibrosis tissue, making it vulnerable to re-injuries. Many physical therapies, such as activity pattern changes [2] and electoral stimulation [3] , are developed against this condition. Although sports performance may be improved, the previously formed scar does not vanish. Therefore, treatments against skeletal muscle fibrosis are required.
Transforming growth factor-β (TGF-β) is a secretory cytokine with key functions in cell secretion, proliferation, differentiation, and other activities [4] . Previous studies have revealed that TGF-β induces fibrosis by increasing the deposition of extracellular matrix (ECM), such as collagen I (Col 1), α smooth muscle actin (SMA), and vimentin (VIM) via the canonical pathway, i.e. the TGF-β/ Smads pathway, in many tissues [5] . Activation of receptors results in Smad2/3 phosphorylation, and the phosphorylated Smad2/3 are then translocated into nucleus and bound with Smad4 to upregulate the transcriptional levels of target genes [6] . Nevertheless, the impact of TGF-β/Smad pathway in the progress of skeletal muscle fibrosis remains to be revealed.
As a group of endogenous, non-coding RNA with a length of~22 nucleotides, microRNAs (miRs) suppress the translation of target genes through binding with the 3′-untranslated regions (3′-UTRs) [7] or trigger the degeneration of target gene mRNAs. Previous reports have demonstrated that miRs play a pivotal role in the fibrotic process [8] [9] [10] . miRs can act as either positive or negative regulators of this pathological change by targeting Smad proteins [11, 12] . Previously, miR-146a-5p (miR-146) has been found to negatively suppress renal fibrosis via TGF-β/Smads pathway by down-regulating Smad4 [13] . However, the role of miR-146 in the fibrosis of skeletal muscle remains unclear.
In the present study, the effect of miR-146 in the progression of skeletal muscle fibrosis was investigated. Based on the in vitro and in vivo results, we found that skeletal muscle fibrosis caused by acute contusion can be mitigated by miR-146 via interfering with TGF-β/Smad4 pathway. The identification of this new anti-fibrosis mechanism in skeletal muscle may provide more information for the development of novel approaches to resolve muscle fibrosis.
Materials and Methods

Animal experiments
Male mice between 2 and 3 months used in this study were obtained from Shanghai Experimental Animal Center. All animal experiments were conducted according to the Declaration of Helsinki and the Guiding Principle in Care and Use of Animals. The experimental protocols were approved by the Animal Care Committee of Fudan University. The acute contusion model of the right tibialis anterior (TA) was constructed according to the previous method [14] . In brief, after anesthetization by intraperitoneal injection with chloral hydrate (0.7 ml/100 g), the right hindlimb of the mouse was fixed on a plate, and the TA was exposed. A stainless steel ball (2 cm in diameter) with a weight of 15 g was released at a height of 1 m as an impactor on the target muscle. The left TA serves as control.
Cell culture, in vitro transfection and luciferase assay Mouse C2C12 myoblasts were purchased from the Shanghai Institutes for Biological Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, USA), and 100 units/ml penicillin, and 100 μg/ml streptomycin. To induce myoblasts into myotubes, FBS was replaced by horse serum (2%, final concentration; Gibco) in culture medium. Cells were maintained in a humidified incubator at 37°C with 5% CO 2 atmosphere. The cells were treated with different concentrations of TGF-β (0, 10, 20, 50, or 100 ng/ml; Sigma, St Louis, USA). The cells were collected after different time (0, 4, 8, and 12 h) of culture. Plasmid transfection in vitro was performed using Lipofectamine LTX (Invitrogen, Carlsbad, USA) according to the manufacturer's instruction. miR-146 mimics (4 and 10 nM), control mimics (10 nM), inhibitor (10 nM), and inhibitor control (10 nM) were transfected into myoblasts using Lipofectamine 2000 following the manufacturer's protocol. The sense sequence of miR-146 mimics is 5′-UGAGAACUGAAUUCCAUGGGUU-3′, of control mimics is 5′-UUCUCCGAACGUGUCACGU-3′, of inhibitor is 5′-AACCCAUGGAAUUCAGUUCUCA-3′, and of inhibitor control is 5′-CAGUACUUUUGUGUAGUACAA-3′. Cells were harvested at 48 h after transfection. The luciferase assays were performed by the Dual-Luciferase Reporter Assay System (Promega, Madison, USA) according to the manufacturer's protocol and determined with a luminometer (Berthold Technologies, Bad Wildbad, Germany).
In vivo transfection
For in vivo transfection, both the plasmids and the miR-146 mimics (10 μM) or control mimics (10 μM) were transfected into TA by electroporation, as previously described [15] . Briefly, the TA was exposed after skin incision, and an injection was performed. Then five electric pulses (50 V/cm) with fixed pulse duration and interval was delivered by the generator (Electro Square porator ECM 830; BTX Harvard Apparatus; Holliston, USA) using two needle electrodes set at the proximal and distal side of the injured TA. Transfection was conducted three days after acute contusion and the mice were sacrificed 4 days after transfection for harvesting injured muscle.
RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from cells or derived tissues using the Trizol reagent (Invitrogen) and quantified by Nanodrop (Thermo Scientific, Waltham, USA). The stem loop RT-PCR (TaqMan; Thermo Scientific) was used to enhance the specificity. Each sample was run in triplicate. The primer sequence used was shown in Table 1 . The ratio of mRNA/U6 (mouse) was calculated based on the delta-delta method [16] .
Histological analysis
Mice were sacrificed and the samples were fixed in 10% neutral buffered formalin for 72 h and were subsequently dehydrated through an alcohol gradient (30%-100%), cleaned, and finally embedded in Table 1 . Primer sequences for RT-PCR
Gene
Sense sequence (5′→3′) Antisense sequence (5′→3′)
ACACTCCAGCTGGGTGAGAACTGAATTCCA CTCAAGTGTCGTGGAGTCGGCAA paraffin wax. Then sections were made perpendicular to the direction of the muscle fiber with 5 μm in thickness using a microtome (SM2500; Leica Microsystems, Wetzlar, Germany). The samples harvested immediately and harvested at 3, 7, and 14 days after contusion were observed using hematoxylin and eosin (HE) stain. Sample sections collected 4 days after electroporation transfection were observed by Masson's trichrome stain or immunohistochemical stain using Smad4 antibody (Sigma). Sections were visualized by inverted light microscopy (IX71SBF2; Olympus Corporation, Tokyo, Japan), with DP72 Manager (Olympus Corporation) to capture digital images.
Western blot analysis
Western blot analysis was performed as previously described [17] . Anti-Col I (Cell Signaling Technology, Danvers, USA), anti-vimentin (Cell Signaling Technology), anti-SMA (Sigma), anti-Smad4 (Sigma), and anti-Tubulin (Sigma) antibodies were used as primary antibodies.
Statistical analysis
Data are presented as the mean ± standard deviation (SD) from samples collected in triplicate. To detect the difference between two groups, Student's t-test was used. To analyze the difference between three or more groups, one-way ANOVA was used. The significance is presented as *P < 0.05, **P < 0.01, and ***P < 0.005. An insignificant difference is expressed as ns. GraphPad Prism 5.0 (GraphPad Software, La Jolla, USA) was used for all statistical analysis.
Results
miR-146 expression is decreased during fibrosis
Acute contusion is a commonly used method to create skeletal muscle injury and the subsequent fibrosis [18, 19] . Our results showed that tissue was most disordered at 7th day while the level of miR-146 was the lowest at the 3rd day after acute contusion (Fig. 1A,B) .
To explore whether TGF-β, a key fibrogenic factor [20] , affects the expression of miR-146 in vitro, C2C12 myotubes were treated with different concentrations of TGF-β for different time. A dosedependent and time-dependent change of miR-146 in response to TGF-β treatment was found. (Fig. 1C,D) , indicating a potential regulation of miR-146 by TGF-β. Furthermore, Smad3 and Smad4, which play key roles in the TGF-β/Smad pathway [21] , were cotransfected into C2C12 cells (Fig. 1E) . After a stable expression of Smad3 and Smad4 in vitro was established, miR-146 was found to After co-transfection of Smad3 and Smad4, the expressions of Smad3 and Smad4 proteins were increased compared with control (E). Correspondingly, the results of RT-qPCR showed that the relatively high level of miR-146 in samples co-transfected with Smad3 and Smad4 plasmids compared with control (F). Data are expressed as the mean ± SD with three independent experiments. *P < 0.05 vs control, **P < 0.01 vs control, and ***P < 0.001 vs control.
be significantly down-regulated (Fig. 1F) . These results indicated that miR-146, which was negatively modulated by Smad proteins, might play a role in the TGF-β/Smad-related pathologies.
miR-146 plays an inhibitory role in the fibrotic process
Then the potential effect of miR-146 in the fibrotic process was explored. After transfection of miR-146 in vitro ( Fig. 2A) , a significant decrease of SMA, VIM, and Col I at both mRNA and protein levels was noticed compared with controls (Fig. 2B,C) . This was further verified in vivo. Three days after acute contusion, in vivo transfection was performed (Fig. 2D) . Four days after transfection, the levels of SMA, VIM, and Col I were found to be significantly decreased by miR-146 treatment compared with control (Fig. 2E) . Together, these data supported an inhibitory role of miR-146 in fibrosis process both in vitro and in vivo.
miR-146 attenuates TGF-β-induced fibrosis
Cells transfected with miR-146 had significantly lower expressions of SMA, VIM, and Col I at both mRNA and protein levels, but both levels were significantly higher in samples transfected with control mimics with concomitant TGF-β treatment. However, this increase was retarded by miR-146, which significantly lowered the mRNA and protein levels of SMA, VIM, and Col I in cells exposed to TGF-β. These results indicated that the anti-fibrotic role of miR-146 might be based on the interference with the TGF-β-related pathway (Fig. 3 ).
Smad4 is a direct target of miR-146
According to in silico (http://www.targetscan.org) analysis and previously published reports [22] , Smad4 is a target gene of miR-146. Therefore the relationship between Smad4 and miR-146 was tested in vitro first. The predicted binding site of miR-146 to Smad4-3′-UTR in human, mouse, and rat was shown in Fig. 4A . The mRNA and protein levels of Smad4 declined significantly by miR-146 mimics compared with control mimics, and those of Smad4 were significantly elevated by the inhibition of miR-146 compared with control ( Fig. 4B,C) . Then whether Smad4 is a direct target of miR-146 in C2C12 cells was further examined. Luciferase activities were suppressed by co-transfection of reporter plasmids containing the 3′-UTR of Smad4 with miR-146 or control mimics (Fig. 4D) , indicating that Smad4-3′-UTR was bound by miR-146. These results proved that miR-146 inhibited TGF-β-induced fibrosis by down-regulating Smad4.
Overexpression of Smad4 attenuated miR-146-mediated anti-fibrosis effect in vivo
Compared with control mimics, miR-146 mimics transfection in vivo significantly declined the mRNA level of Smad4, which was, however, up-regulated by co-transfection of Smad4 and miR-146 (Fig. 5A) . Next, the fibrotic process was examined. The mRNA levels of SMA, VIM, and Col I of the injured samples were significantly decreased after miR-146 transfection compared with control, but simultaneous treatment with Smad4 and miR-146 significantly elevated the mRNA levels of these fibrotic markers (Fig. 5B) . Changes of SMA, VIM, and Col I at protein level as determined by western blot analysis were similar to those found at the mRNA level (Fig. 5C ). This was further confirmed by histological analysis. Seven days after acute contusion, collagen deposition was noted with higher Smad4 expression compared with normal skeletal muscle. Transfection of miR-146 mimics decreased the expressions of collagen and Smad4. However, cotransfection of miR-146 mimics and Smad4 reversed the effect of miR-146. Apart from a significantly higher Smad4 level, collagen became more evident (Fig. 5D) . These results verified that miR-146 attenuated the fibrosis of skeletal muscle by down-regulating Smad4.
Discussion
Excessive deposition of ECM is the hallmark of skeletal muscle fibrosis. In the present study, miR-146 is found to be lowly expressed in The mRNA levels of SMA, VIM, and Col I were analyzed after in vivo transfection with miR-146 or control mimics. Data are expressed as the mean ± SD with three independent experiments. *P < 0.05 vs control, **P < 0.01 vs control, and ***P < 0.001 vs control.
the model of fibrosis in vitro and in vivo. Overexpression of miR-146 attenuates the secretion ECM in vitro as well as the fibrotic process in vivo. It is down-regulated by Smad protein, and it represses the expression of Smad4. Our results suggest a therapeutic potential of miR-146 against skeletal muscle fibrosis after injury. TGF-β is a pivotal pro-fibrogenic cytokine [23] , and miR-146 has been proven to be a pivotal anti-fibrotic miRNA in many tissues [24, 25] . Our results demonstrated an anti-fibrotic effect of miR-146 in a dose-and time-dependent manner in the TGF-β-treated C2C12 myotubes. TGF-β promotes fibrotic cascades by eliciting the conversion of myoblasts into myofibroblasts, which is an important event in the development of skeletal muscle fibrosis [20] . This transdifferentiation is marked by the expression of SMA at both mRNA and protein levels. TGF-β also has the ability to induce the synthesis of collagen of fibroblasts [26] . As a predominant component of ECM, Col I is overexpressed in fibrogenetic process [26, 27] . As a mesenchymal marker, increased expression level of VIM indicates a transdifferentiation into mesenchyme [28] . In this study, we found higher levels of SMA, Col I, and VIM in fibrosis models in vivo and in vitro, indicating the fibrotic characteristics of these samples, and that miR-146 overexpression significantly suppressed this pathology. These observations support that miR-146 inhibits skeletal muscle fibrosis by down-regulating the expression of ECM and retarding the transdifferentiation process.
As a member of the TGF-β canonical signaling pathway, Smad4 enables the phosphorylated Smad2 and Smad3 to be transported into the nucleus and enhances the expressions of targets genes such as Col I, while Smad7 inhibits the phosphorylation in a competitive manner [29] . miRs can either positively or negatively participate in the process of fibrosis by interacting with Smad family. It has been proven that miR-877 enhances lung fibrosis by degrading Smad7 [12] . miR-145 down-regulates Smad3 and attenuates cystic fibrosis [30] . miR-146 Figure 3 . miR-146 attenuates TGF-β-induced fibrosis C2C12 myotubes were transfected with miR-146 or control mimics in the presence or absence of TGF-β (20 ng/ml, 2 days). Then the mRNA (A) and protein (B) levels of VIM, SMA, and Col I were analyzed by RT-qPCR and western blot analysis, respectively. Data are expressed as the mean ± SD with three independent experiments. *P < 0.05 vs control, **P < 0.01 vs control, and ***P < 0.001 vs control. NC: nonsense control. Luciferase reporter containing Smad4 3′-UTR sequences was co-transfected into C2C12 myoblasts with miR-146 or control mimics. Forty-eight hours after transfection, Renilla luciferase activity was measured and normalized to firefly luciferase activity. NC: nonsense control. miR-146a-5p is a negative regulator of TGF-β signaling has been reported to be an inhibitor in the TGF-β/Smad signaling pathway by suppressing Smad4 [31] . Furthermore, this microRNA shows the ability to alleviate fibrosis through interfering with this pathway in many tissues [13, 22] . Here, in the C2C12 muscle cells, miR-146 was also found to bind with the 3′-UTR of Smad4. Upregulating miR-146 significantly blocked the expression of Smad4, hence, weakening the signal cascade and alleviating the fibrotic process. Again, these data suggested that the anti-fibrogenic role of miR-146 was developed by moderating Smad4 expression.
Interestingly, in our study, miR-146 was found to be decreased after skeletal muscle injury in TGF-β treated cells, which was inconsistent with previous studies. Nakasa et al. [32] found that miR-146 was up-regulated in synovial tissue samples in both rheumatoid arthritis and osteoarthritis patients. Similar fluctuation pattern was also revealed in diabetic nephropathy [33, 34] . This discrepancy may be a result of different cell lines and pathology models used. However, this discrepancy did not undermine its anti-fibrotic function. The identification of the TGF-β/miR-146/Smad4 signal pathway shows new potential against skeletal muscle fibrosis. Previous studies have shown the possibility to treat fibrosis by interfering with TGF-β/Smads signaling pathway [35, 36] , especially with the use of miR-146 [13, 37] . The current findings may extend its use in skeletal muscle. Artificially elevated miR-146 level could lower the levels of fibrotic markers both in vitro and in vivo. However, further studies are required to explore the changes of various properties of miR-146-treated cells and the physiological and sports performance of the recovered muscle.
In conclusion, we demonstrated that miR-146 inhibits skeletal muscle fibrosis by suppressing TGF-β/Smad4 signaling pathway. miR-146 plays a negative role in the development of skeletal muscle fibrosis, and it may have therapeutic potential to reduce skeletal muscle fibrosis after injury.
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